Form 4 for CAI Caris Life Sciences, Inc.
Accepted 2025-12-12 00:00:00 ET · period of report 2025-12-11 · accession 0002072013-25-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-12-12 | 2025-12-11 | CAI | Power Luke Thomas | See Remarks | M - OptEx | $2.44 | +62.2K | 161.8K | +63% | +$151.9K |
| DM | 2025-12-12 | 2025-12-11 | CAI | Power Luke Thomas | See Remarks | S - Sale+OE | $26.57 | -62.2K | 101.0K | -38% | -$1.65M |
| DM | 2025-12-12 | 2025-12-11 | CAI | Power Luke Thomas | See Remarks | M - OptEx | $0.00 | -62.2K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-11 | M | A | 24,750 | $2.44 | 124,321 | D | — | — | |
| 2 | Common | Common Stock | 2025-12-11 | S | D | 1,400 | $27.16 | 99,571 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $27.20, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2025-12-11 | S | D | 60,850 | $26.56 | 100,971 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.11 to $27.07, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2025-12-11 | M | A | 37,500 | $2.44 | 161,821 | D | — | — | |
| 5 | Derivative | Stock Option | 2025-12-11 | M | D | 24,750 | $0.00 | 0 | D | $2.44 · — to 2027-05-30 | 24,750 Common Stock | (F4) The stock option is fully vested and exercisable. |
| 6 | Derivative | Stock Option | 2025-12-11 | M | D | 37,500 | $0.00 | 0 | D | $2.44 · — to 2028-11-14 | 37,500 Common Stock | (F4) The stock option is fully vested and exercisable. |